On 12 September 2024, Genentech (a member of the Roche Group) announced that its Tecentriq Hybreza™ (atezolizumab and hyaluronidase-tqjs) received FDA approval, and is the first and only US approved PD-(L)1 inhibitor for subcutaneous (SC) administration.
Genentech states that the SC option reduces treatment time to around 7 minutes compared with 30-60 minutes for IV infusion. Tecentriq Hybreza™ will be available for all IV indications of Tecentriq® including certain types of lung, liver, skin and soft tissue cancer.
Tecentriq Hybreza™ is marketed outside the US as Tecentriq® SC and was first approved in the UK in August 2023. It has since been approved in other countries, including in Europe (January 2024) and Australia (February 2024, recommended for PBS listing in April 2024).